Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Paul Stephen Aisen, MD

    TitleProfessor of Neurology
    SchoolKeck School of Medicine of USC
    DepartmentNeurology
    AddressATRI 9860 Mesa Rim Road
    Health Sciences Campus
    San Diego California 92121
    vCardDownload vCard
      Other Positions
      TitleDirector, Alzheimer's Therapeutic Research Institute


      Collapse Overview 
      Collapse Overview
      Paul Aisen, M.D., has been appointed founding director of USC ATRI. Aisen has been a leading figure in Alzheimer’s disease research for more than two decades, having developed novel methodologies as well as designed and directed many large therapeutic trials. He received his B.A. in biochemistry and molecular biology from Harvard and his medical degree from Columbia. He completed his residency at Case Western Reserve University in Cleveland and Mount Sinai Medical Center in New York, and then fellowship training in rheumatology at New York University. After serving as chief medical resident at Mount Sinai, he began a solo practice in internal medicine and rheumatology in New York. Aisen joined the faculty of Mount Sinai in 1994 and was recruited to Georgetown University in 1999 as a professor of neurology and medicine. That year, he founded the Memory Disorders Program, a clinical and research program for Alzheimer’s disease and related disorders. He continued basic research studies on therapeutic targets and biomarkers and designed and directed multicenter therapeutic trials. He became vice chair of the Department of Neurology at Georgetown in 2004. From 2007 through 2015, he was professor in the Department of Neurosciences at the University of California, San Diego and director of the Alzheimer’s Disease Cooperative Study.


      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge KC, Wessels AM, Hendrix S, Aisen P, Siemers E. Statistical properties of continuous composite scales and implications for drug development. J Biopharm Stat. 2017 Apr 12. PMID: 28402165.
        View in: PubMed
      2. Tosun D, Landau S, Aisen P, Petersen RC, Mintun M, Jagust W, Weiner MW. Association between tau deposition and antecedent amyloid-ß accumulation rates in normal and early symptomatic individuals. Brain. 2017 Mar 17. PMID: 28334939.
        View in: PubMed
      3. Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen P, Johnson KA, Sperling RA. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated ß-amyloid. Alzheimers Dement. 2017 Feb 27. PMID: 28253478.
        View in: PubMed
      4. Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen P, Turner RS. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation. 2017 Jan 03; 14(1):1. PMID: 28086917.
        View in: PubMed
      5. Weiner MW, Veitch DP, Aisen P, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Salazar J, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimers Dement. 2016 Dec 05. PMID: 27931796.
        View in: PubMed
      6. Sokolow S, Li X, Chen L, D Taylor K, Rotter JI, Rissman RA, Aisen P, Apostolova LG. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. J Alzheimers Dis. 2016 Nov 29. PMID: 27911294.
        View in: PubMed
      7. Cummings J, Aisen P, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimers Res Ther. 2016; 8:39. PMID: 27646601.
        View in: PubMed
      8. Insel PS, Donohue MC, Mackin RS, Aisen P, Hansson O, Weiner MW, Mattsson N. Cognitive and functional changes associated with Aß pathology and the progression to mild cognitive impairment. Neurobiol Aging. 2016 Aug 26; 48:172-181. PMID: 27710807.
        View in: PubMed
      9. Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen P, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. BMC Med Genomics. 2016; 9 Suppl 1:30. PMID: 27535542.
        View in: PubMed
      10. Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen P, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimers Res Ther. 2016; 8:25. PMID: 27358067.
        View in: PubMed
      11. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR, Jagust WJ, Aisen P, Weiner MW, Saykin AJ. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 Jun 1; 73(6):721-32. PMID: 27088965.
        View in: PubMed
      12. Sano M, Aisen P, Andrews HF, Tsai WY, Lai F, Dalton AJ. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. 2016 May 31; 86(22):2071-6. PMID: 27164691.
        View in: PubMed
      13. Weninger S, Carrillo MC, Dunn B, Aisen P, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimers Dement. 2016 May; 12(5):631-2. PMID: 27157073.
        View in: PubMed
      14. Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen P, Jagust WJ, Weiner MW. Accelerating rates of cognitive decline and imaging markers associated with ß-amyloid pathology. Neurology. 2016 May 17; 86(20):1887-96. PMID: 27164667.
        View in: PubMed
      15. Rentz DM, Dekhtyar M, Sherman J, Burnham S, Blacker D, Aghjayan SL, Papp KV, Amariglio RE, Schembri A, Chenhall T, Maruff P, Aisen P, Hyman BT, Sperling RA. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. J Prev Alzheimers Dis. 2016 Mar; 3(1):8-12. PMID: 26998469.
        View in: PubMed
      16. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar; 12(3):292-323. PMID: 27012484.
        View in: PubMed
      17. Thomas RG, Albert M, Petersen RC, Aisen P. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. Alzheimers Dement. 2016 May; 12(5):598-603. PMID: 26917500.
        View in: PubMed
      18. Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen P, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S. CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nat Rev Neurol. 2016 Jan; 12(1):56-61. PMID: 26416539.
        View in: PubMed
      19. Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen P, Hampel H. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. J Alzheimers Dis. 2015 Sep 24; 48 Suppl 1:S171-91. PMID: 26402088.
        View in: PubMed
      20. Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen P, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Front Behav Neurosci. 2015; 9:239. PMID: 26441570.
        View in: PubMed
      21. Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen P. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015 Oct 20; 85(16):1383-91. PMID: 26362286.
        View in: PubMed
      22. Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, Aisen P, Petersen RC, Jack CR, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain. 2015 Oct; 138(Pt 10):3076-88. PMID: 26268530.
        View in: PubMed
      23. Andrieu S, Coley N, Lovestone S, Aisen P, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. Lancet Neurol. 2015 Sep; 14(9):926-44. PMID: 26213339.
        View in: PubMed
      24. Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015 Jul 9; 47(1):205-14. PMID: 26402769.
        View in: PubMed
      25. Aisen P, Petersen RC, Donohue M, Weiner MW. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimers Dement. 2015 Jul; 11(7):734-9. PMID: 26194309.
        View in: PubMed
      26. Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen P, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimers Dement. 2015 Jul; 11(7):772-91. PMID: 26194312.
        View in: PubMed
      27. Beckett LA, Donohue MC, Wang C, Aisen P, Harvey DJ, Saito N. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimers Dement. 2015 Jul; 11(7):823-31. PMID: 26194315.
        View in: PubMed
      28. Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimers Res Ther. 2015; 7(1):39. PMID: 26120368.
        View in: PubMed
      29. Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimers Res Ther. 2015; 7(1):43. PMID: 26120369.
        View in: PubMed
      30. Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen P. Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1):36. PMID: 26064192.
        View in: PubMed
      31. Weiner MW, Veitch DP, Aisen P, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, Shen L, Schwarz A, Toga AW, Trojanowski JQ. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 2015 Jun; 11(6):e1-e120. PMID: 26073027.
        View in: PubMed
      32. Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR, Beckett LA, Aisen P, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimers Dement. 2015 Dec; 11(12):1417-29. PMID: 25960448.
        View in: PubMed
      33. Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW. Predicting Reduction of Cerebrospinal Fluid ß-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurol. 2015 May 1; 72(5):554-60. PMID: 25775167.
        View in: PubMed
      34. Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen P, Sperling RA. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's disease cooperative study cognitive function instrument. JAMA Neurol. 2015 Apr 1; 72(4):446-54. PMID: 25706191.
        View in: PubMed
      35. Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR, DeCarli C, Petersen R, Aisen P, Weiner MW, Mackin RS. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. Am J Geriatr Psychiatry. 2016 Feb; 24(2):126-35. PMID: 26238228.
        View in: PubMed
      36. Rafii MS, Aisen P. Advances in Alzheimer's disease drug development. BMC Med. 2015; 13(1):62. PMID: 25857341.
        View in: PubMed
      37. Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen P, Weiner MW. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol. 2015 May; 2(5):534-47. PMID: 26000325.
        View in: PubMed
      38. Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen P, Petersen RC, Green RC, Jack CR, Weiner MW, Baldwin CT, Lunetta KL, Farrer LA. Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol. 2015 Mar; 77(3):547-52. PMID: 25559091.
        View in: PubMed
      39. Mattsson N, Insel PS, Aisen P, Jagust W, Mackin S, Weiner M. Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 2015 Mar 17; 84(11):1136-44. PMID: 25681451.
        View in: PubMed
      40. Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis. 2015 Jan 1; 43(3):949-55. PMID: 25125457.
        View in: PubMed
      41. Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen P, Lista S. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother. 2015 Jan; 15(1):83-105. PMID: 25537424.
        View in: PubMed
      42. Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dement Geriatr Cogn Dis Extra. 2014 Sep-Dec; 4(3):509-16. PMID: 25685141.
        View in: PubMed
      43. Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen P, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW. The transitional association between ß-amyloid pathology and regional brain atrophy. Alzheimers Dement. 2015 Oct; 11(10):1171-9. PMID: 25499535.
        View in: PubMed
      44. Rueda AD, Lau KM, Saito N, Harvey D, Risacher SL, Aisen P, Petersen RC, Saykin AJ, Farias ST. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimers Dement. 2015 Sep; 11(9):1080-9. PMID: 25449531.
        View in: PubMed
      45. Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen P, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimers Dement. 2015 Sep; 11(9):1069-79. PMID: 25301682.
        View in: PubMed
      46. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S430-52. PMID: 25341459.
        View in: PubMed
      47. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen P. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 2014 Aug; 71(8):961-70. PMID: 24886908.
        View in: PubMed
      48. Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR, Aisen P, Shaw LM, Trojanowski JQ, Weiner MW. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiol Aging. 2015 Jan; 36(1):273-82. PMID: 25175807.
        View in: PubMed
      49. Ryman DC, Acosta-Baena N, Aisen P, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014 Jul 15; 83(3):253-60. PMID: 24928124.
        View in: PubMed
      50. Weiner MW, Veitch DP, Hayes J, Neylan T, Grafman J, Aisen P, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Shaw LM, Saykin AJ, Green RC, Harvey D, Toga AW, Friedl KE, Pacifico A, Sheline Y, Yaffe K, Mohlenoff B. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2014 Jun; 10(3 Suppl):S226-35. PMID: 24924673.
        View in: PubMed
      51. Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen P. Alzheimer's disease cooperative study prevention instrument project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. J Am Geriatr Soc. 2014 May; 62(5):985-8. PMID: 24828933.
        View in: PubMed
      52. Doody RS, Farlow M, Aisen P. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014 Apr 10; 370(15):1460. PMID: 24716687.
        View in: PubMed
      53. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen P. Clinical trial of an inhibitor of RAGE-Aß interactions in Alzheimer disease. Neurology. 2014 Apr 29; 82(17):1536-42. PMID: 24696507.
        View in: PubMed
      54. Aisen P. Serum brain-derived neurotrophic factor and the risk for dementia. JAMA. 2014 Apr 23-30; 311(16):1684-5. PMID: 24756518.
        View in: PubMed
      55. Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR, Weiner MW, Dartigues JF, Aisen P. Estimating long-term multivariate progression from short-term data. Alzheimers Dement. 2014 Oct; 10(5 Suppl):S400-10. PMID: 24656849.
        View in: PubMed
      56. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014 Mar 19; 6(228):228fs13. PMID: 24648338.
        View in: PubMed
      57. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen P, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23; 370(4):311-21. PMID: 24450890.
        View in: PubMed
      58. Burstein AH, Grimes I, Galasko DR, Aisen P, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. BMC Neurol. 2014; 14:12. PMID: 24423155.
        View in: PubMed
      59. Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen P, Dubois B. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol. 2014 Apr 15; 88(4):426-49. PMID: 24275164.
        View in: PubMed
      60. Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen P, Christensen JJ, Ercole L, Hornbeck RC, Farrar AM, Aldea P, Jasielec MS, Owen CJ, Xie X, Mayeux R, Brickman A, McDade E, Klunk W, Mathis CA, Ringman J, Thompson PM, Ghetti B, Saykin AJ, Sperling RA, Johnson KA, Salloway S, Correia S, Schofield PR, Masters CL, Rowe C, Villemagne VL, Martins R, Ourselin S, Rossor MN, Fox NC, Cash DM, Weiner MW, Holtzman DM, Buckles VD, Moulder K, Morris JC. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):E4502-9. PMID: 24194552.
        View in: PubMed
      61. Tractenberg RE, Yumoto F, Aisen P. Detecting When "Quality of Life" Has Been "Enhanced": Estimating Change in Quality of Life Ratings. Open J Philos. 2013 Nov 01; 3(4A):24-31. PMID: 26213645.
        View in: PubMed
      62. Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen P. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2014 Mar; 29(2):159-65. PMID: 24164929.
        View in: PubMed
      63. Doody RS, Aisen P, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Oct 24; 369(17):1661. PMID: 24152267.
        View in: PubMed
      64. Sano M, Egelko S, Donohue M, Ferris S, Kaye J, Hayes TL, Mundt JC, Sun CK, Paparello S, Aisen P. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Dis Assoc Disord. 2013 Oct-Dec; 27(4):356-62. PMID: 23151596.
        View in: PubMed
      65. Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. PLoS One. 2013; 8(9):e74062. PMID: 24040166.
        View in: PubMed
      66. Weiner MW, Veitch DP, Aisen P, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep; 9(5):e111-94. PMID: 23932184.
        View in: PubMed
      67. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013 Aug; 74(2):199-208. PMID: 23686697.
        View in: PubMed
      68. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen P. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25; 369(4):341-50. PMID: 23883379.
        View in: PubMed
      69. Kim S, Swaminathan S, Inlow M, Risacher SL, Nho K, Shen L, Foroud TM, Petersen RC, Aisen P, Soares H, Toledo JB, Shaw LM, Trojanowski JQ, Weiner MW, McDonald BC, Farlow MR, Ghetti B, Saykin AJ. Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. PLoS One. 2013; 8(7):e70269. PMID: 23894628.
        View in: PubMed
      70. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, Sperling R, Wilcock GK, Fox N, Scheltens P, Touchon J, Hendrix S, Andrieu S, Aisen P. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement. 2013 Jul; 9(4):438-44. PMID: 23809364.
        View in: PubMed
      71. Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen P. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013 Jul; 27(4):391-401. PMID: 23876113.
        View in: PubMed
      72. Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, DeCarli C, Jack CR, Petersen RC, Aisen P, Cummings JL, Toga AW, Thompson PM. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord. 2013 Apr-Jun; 27(2):174-81. PMID: 23694947.
        View in: PubMed
      73. Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR, Aisen P, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci. 2013; 5:11. PMID: 23554593.
        View in: PubMed
      74. Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, Inlow M, Foroud T, Jagust WJ, Koeppe RA, Mathis CA, Shaw LM, Trojanowski JQ, Soares H, Aisen P, Petersen RC, Weiner MW, Saykin AJ. Association of plasma and cortical amyloid beta is modulated by APOE e4 status. Alzheimers Dement. 2014 Jan; 10(1):e9-e18. PMID: 23541187.
        View in: PubMed
      75. Aisen P, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nat Rev Drug Discov. 2013 Apr; 12(4):324. PMID: 23493086.
        View in: PubMed
      76. Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Aisen P. Health-related resource use and costs in elderly adults with and without mild cognitive impairment. J Am Geriatr Soc. 2013 Mar; 61(3):396-402. PMID: 23414481.
        View in: PubMed
      77. Mackin RS, Insel P, Tosun D, Mueller SG, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Lee JY, Jack CR, Aisen P, Petersen RC, Weiner MW. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. Am J Geriatr Psychiatry. 2013 Sep; 21(9):906-14. PMID: 23567388.
        View in: PubMed
      78. Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. JAMA Neurol. 2013 Feb; 70(2):270-1. PMID: 23400724.
        View in: PubMed
      79. Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen P, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb; 12(2):207-16. PMID: 23332364.
        View in: PubMed
      80. Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, Aisen P, Jagust WJ, Weiner MW, Jack CR. Focal hemosiderin deposits and ß-amyloid load in the ADNI cohort. Alzheimers Dement. 2013 Oct; 9(5 Suppl):S116-23. PMID: 23375568.
        View in: PubMed
      81. Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 2013 Jan 15; 80(3):282-8. PMID: 23255824.
        View in: PubMed
      82. Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, Foroud TM, Mukherjee S, Crane PK, Aisen P, Petersen RC, Weiner MW, Saykin AJ. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav. 2012 Dec; 6(4):634-48. PMID: 22865056.
        View in: PubMed
      83. Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen P, Weiner MW, Jagust WJ. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012 Oct; 72(4):578-86. PMID: 23109153.
        View in: PubMed
      84. Morris JC, Aisen P, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, Oliver A, Quaid K, Ringman JM, Rossor MN, Salloway S, Schofield PR, Selsor NJ, Sperling RA, Weiner MW, Xiong C, Moulder KL, Buckles VD. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2012 Oct 1; 2(10):975-984. PMID: 23139856.
        View in: PubMed
      85. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov. 2012 Sep; 11(9):655-6. PMID: 22935789.
        View in: PubMed
      86. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen P, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30; 367(9):795-804. PMID: 22784036.
        View in: PubMed
      87. Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012 Jul; 69(7):901-5. PMID: 22431834.
        View in: PubMed
      88. Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen P, Weiner MW, Petersen RC, Knopman DS. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol. 2012 Jul; 69(7):856-67. PMID: 22409939.
        View in: PubMed
      89. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012 Jul; 69(7):836-41. PMID: 22431837.
        View in: PubMed
      90. Farlow M, Arnold SE, van Dyck CH, Aisen P, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012 Jul; 8(4):261-71. PMID: 22672770.
        View in: PubMed
      91. Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen P, Sperling RA, Dale AM. Amyloid-ß--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun; 69(6):709-13. PMID: 22529247.
        View in: PubMed
      92. Reiman EM, Brinton RD, Katz R, Petersen RC, Negash S, Mungas D, Aisen P. Considerations in the design of clinical trials for cognitive aging. J Gerontol A Biol Sci Med Sci. 2012 Jun; 67(7):766-72. PMID: 22573913.
        View in: PubMed
      93. Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen P. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012 Mar; 69(3):368-72. PMID: 22410444.
        View in: PubMed
      94. Aisen P, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Mar; 2(3):a006395. PMID: 22393531.
        View in: PubMed
      95. Rissman RA, Trojanowski JQ, Shaw LM, Aisen P. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm. 2012 Jul; 119(7):843-50. PMID: 22354745.
        View in: PubMed
      96. Tractenberg RE, Yumoto F, Aisen P, Kaye JA, Mislevy RJ. Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost". PLoS One. 2012; 7(2):e30019. PMID: 22363411.
        View in: PubMed
      97. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, Casey BJ, Chang L, Ernst TM, Gruen JR, Jernigan TL, Kaufmann WE, Kenet T, Kennedy DN, Kuperman JM, Murray SS, Sowell ER, Rimol LM, Mattingsdal M, Melle I, Agartz I, Andreassen OA, Schork NJ, Dale AM. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A. 2012 Mar 6; 109(10):3985-90. PMID: 22343285.
        View in: PubMed
      98. Sperling RA, Jack CR, Aisen P. Testing the right target and right drug at the right stage. Sci Transl Med. 2011 Nov 30; 3(111):111cm33. PMID: 22133718.
        View in: PubMed
      99. Weiner MW, Veitch DP, Aisen P, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb; 8(1 Suppl):S1-68. PMID: 22047634.
        View in: PubMed
      100. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, Petersen RC, Schuff N, Weiner MW. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex. 2012 Sep; 22(9):1993-2004. PMID: 22038908.
        View in: PubMed
      101. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen P, Brewer JB, Hyman BT, Dale AM. Amyloid-ß associated volume loss occurs only in the presence of phospho-tau. Ann Neurol. 2011 Oct; 70(4):657-61. PMID: 22002658.
        View in: PubMed
      102. Aisen P. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiol Aging. 2011 Dec; 32 Suppl 1:S64-6. PMID: 21983242.
        View in: PubMed
      103. Vellas B, Aisen P, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol. 2011 Dec; 95(4):594-600. PMID: 21925234.
        View in: PubMed
      104. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen P, Petersen RC, Weiner MW. Impact of apolipoprotein E4-cerebrospinal fluid ß-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement. 2011 Sep; 7(5):514-20. PMID: 21889115.
        View in: PubMed
      105. Aisen P. Q&A: The Alzheimer's Disease Neuroimaging Initiative. BMC Med. 2011; 9:101. PMID: 21884605.
        View in: PubMed
      106. Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen P, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011 Dec; 68(12):1526-35. PMID: 21825215.
        View in: PubMed
      107. Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen P. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011 Aug; 68(8):853-61. PMID: 21810649.
        View in: PubMed
      108. Toledo JB, Vanderstichele H, Figurski M, Aisen P, Petersen RC, Weiner MW, Jack CR, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM. Factors affecting Aß plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011 Oct; 122(4):401-13. PMID: 21805181.
        View in: PubMed
      109. Mackin RS, Insel P, Aisen P, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry. 2012 Apr; 27(4):355-63. PMID: 21744390.
        View in: PubMed
      110. Vellas B, Pesce A, Robert PH, Aisen P, Ancoli-Israel S, Andrieu S, Cedarbaum J, Dubois B, Siemers E, Spire JP, Weiner MW, May TS. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimers Dement. 2011 Jul; 7(4):e109-17. PMID: 21784343.
        View in: PubMed
      111. Sabbagh MN, Agro A, Bell J, Aisen P, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Jul-Sep; 25(3):206-12. PMID: 21192237.
        View in: PubMed
      112. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen P, Weiner MW, Jagust WJ. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011 Oct; 68(10):1257-66. PMID: 21670386.
        View in: PubMed
      113. Aisen P. Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em. Alzheimers Dement. 2011 May; 7(3):e48-50. PMID: 21575868.
        View in: PubMed
      114. Sperling RA, Aisen P, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May; 7(3):280-92. PMID: 21514248.
        View in: PubMed
      115. Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen P, Weiner M, Petersen RC, Jack CR. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain. 2011 May; 134(Pt 5):1479-92. PMID: 21478184.
        View in: PubMed
      116. Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen P. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Dis Assoc Disord. 2011 Apr-Jun; 25(2):122-7. PMID: 20921876.
        View in: PubMed
      117. Aisen P, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011 Feb; 7(1):102-11. PMID: 22291741.
        View in: PubMed
      118. Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, Andrieu S, Weiner MW, Carrillo MC, Bain LJ. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement. 2011 Mar; 7(2):127-32. PMID: 21414553.
        View in: PubMed
      119. Donohue MC, Gamst AC, Aisen P. Requiring an amyloid-ß1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement. 2011 Mar; 7(2):245-6; author reply 247-9. PMID: 21414558.
        View in: PubMed
      120. Weigand SD, Vemuri P, Wiste HJ, Senjem ML, Pankratz VS, Aisen P, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, Jack CR. Transforming cerebrospinal fluid Aß42 measures into calculated Pittsburgh Compound B units of brain Aß amyloid. Alzheimers Dement. 2011 Mar; 7(2):133-41. PMID: 21282074.
        View in: PubMed
      121. Niikura T, Sidahmed E, Hirata-Fukae C, Aisen P, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. PLoS One. 2011; 6(1):e16259. PMID: 21264226.
        View in: PubMed
      122. Bateman RJ, Aisen P, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther. 2011; 3(1):1. PMID: 21211070.
        View in: PubMed
      123. Rammouz G, Lecanu L, Aisen P, Papadopoulos V. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. J Alzheimers Dis. 2011; 24 Suppl 2:5-16. PMID: 21335661.
        View in: PubMed
      124. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol. 2011 Dec; 95(4):579-93. PMID: 21130138.
        View in: PubMed
      125. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen P. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 Nov 3; 304(17):1903-11. PMID: 21045096.
        View in: PubMed
      126. McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimers Dement. 2010 Nov; 6(6):482-93. PMID: 21044778.
        View in: PubMed
      127. Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen P, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010 Nov; 133(11):3336-48. PMID: 20935035.
        View in: PubMed
      128. Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen P, Jack CR, Weiner MW. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging. 2012 May; 33(5):845-55. PMID: 20855131.
        View in: PubMed
      129. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen P, Petersen RC, Fleisher AS. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010 Sep; 6(5):412-9. PMID: 20813342.
        View in: PubMed
      130. McEvoy LK, Edland SD, Holland D, Hagler DJ, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen P, Brewer JB, Dale AM. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):269-77. PMID: 20683184.
        View in: PubMed
      131. Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen P, Jagust WJ, Koeppe RA, Mathis CA, Weiner MW, Thompson PM. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging. 2010 Aug; 31(8):1284-303. PMID: 20538372.
        View in: PubMed
      132. Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiol Aging. 2010 Aug; 31(8):1340-54. PMID: 20570401.
        View in: PubMed
      133. Tractenberg RE, Fillenbaum G, Aisen P, Liebke DE, Yumoto F, Kuchibhatla MN. What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. Curr Gerontol Geriatr Res. 2010; 510614. PMID: 20585350.
        View in: PubMed
      134. Aisen P, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jagust W, Toga AW, Saykin AJ, Morris JC, Green RC, Weiner MW. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010 May; 6(3):239-46. PMID: 20451872.
        View in: PubMed
      135. Weiner MW, Aisen P, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010 May; 6(3):202-11.e7. PMID: 20451868.
        View in: PubMed
      136. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen P, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR, Jagust W, Toga AW, Lee VM, Shaw LM. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010 May; 6(3):230-8. PMID: 20451871.
        View in: PubMed
      137. Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen P, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Hum Brain Mapp. 2010 May; 31(5):786-97. PMID: 20143386.
        View in: PubMed
      138. Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen P, Lowe DA, Fillit HM. Therapeutics for cognitive aging. Ann N Y Acad Sci. 2010 Apr; 1191 Suppl 1:E1-15. PMID: 20392284.
        View in: PubMed
      139. Edland SD, Emond JA, Aisen P, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Dis Assoc Disord. 2010 Apr-Jun; 24(2):159-64. PMID: 20505433.
        View in: PubMed
      140. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement. 2010 Mar; 6(2):89-97. PMID: 20298968.
        View in: PubMed
      141. Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen P, Weiner M, Petersen RC, Jack CR. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol. 2010 Mar; 67(3):308-16. PMID: 20373342.
        View in: PubMed
      142. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen P, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010 Jan; 9(1):119-28. PMID: 20083042.
        View in: PubMed
      143. Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol. 2010 Jun; 223(2):334-46. PMID: 19815015.
        View in: PubMed
      144. Raman R, Thomas RG, Weiner MW, Jack CR, Ernstrom K, Aisen P, Tariot PN, Quinn JF. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):333-6. PMID: 19571733.
        View in: PubMed
      145. Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen P. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Dis Assoc Disord. 2009 Oct-Dec; 23(4):315-8. PMID: 19571732.
        View in: PubMed
      146. Aisen P. Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther. 2009; 1(1):2. PMID: 19674435.
        View in: PubMed
      147. Tariot PN, Aisen P. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry. 2009 Jun; 70(6):919-21. PMID: 19573485.
        View in: PubMed
      148. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen P, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr; 65(4):403-13. PMID: 19296504.
        View in: PubMed
      149. Vozdolska R, Sano M, Aisen P, Edland SD. The net effect of alternative allocation ratios on recruitment time and trial cost. Clin Trials. 2009 Apr; 6(2):126-32. PMID: 19342464.
        View in: PubMed
      150. Tractenberg RE, Aisen P. Agreement in cognitive and clinical assessments in Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(4):344-52. PMID: 19293567.
        View in: PubMed
      151. Aisen P. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. Alzheimers Dement. 2009 Mar; 5(2):125-7. PMID: 19328440.
        View in: PubMed
      152. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement. 2009 Mar; 5(2):85-92. PMID: 19328434.
        View in: PubMed
      153. Rafii MS, Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009; 7:7. PMID: 19228370.
        View in: PubMed
      154. Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen P. Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behav Neurol. 2009; 21(1):129-36. PMID: 19847051.
        View in: PubMed
      155. Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. J Alzheimers Dis. 2009; 16(2):235-70. PMID: 19221415.
        View in: PubMed
      156. Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen P, Matsuoka Y. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neurosci Lett. 2009 Jan 23; 450(1):51-5. PMID: 19022346.
        View in: PubMed
      157. Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen P. Plasma urate and progression of mild cognitive impairment. Neurodegener Dis. 2009; 6(1-2):23-8. PMID: 19066433.
        View in: PubMed
      158. Aisen P, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008 Oct 15; 300(15):1774-83. PMID: 18854539.
        View in: PubMed
      159. Aisen P. Amyloid-based therapeutics: findings translated into novel treatments. CNS Spectr. 2008 Oct; 13(10 Suppl 16):36-8. PMID: 18955961.
        View in: PubMed
      160. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen P, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol. 2008 Aug; 65(8):1031-8. PMID: 18695053.
        View in: PubMed
      161. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen P, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19; 372(9634):207-15. PMID: 18640457.
        View in: PubMed
      162. Aisen P. Treatment for MCI: is the evidence sufficient? Neurology. 2008 May 27; 70(22):2020-1. PMID: 18505976.
        View in: PubMed
      163. Haigh JR, Johnston SR, Peppernay A, Mattern PJ, Garcia GE, Doctor BP, Gordon RK, Aisen P. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: next generation prophylaxis and sequestering of acetylcholinesterase over butyrylcholinesterase. Chem Biol Interact. 2008 Sep 25; 175(1-3):380-6. PMID: 18572153.
        View in: PubMed
      164. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen P, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimers Dement. 2008 May; 4(3):156-63. PMID: 18631960.
        View in: PubMed
      165. Aisen P. Tarenflurbil: a shot on goal. Lancet Neurol. 2008 Jun; 7(6):468-9. PMID: 18450518.
        View in: PubMed
      166. Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen P, Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008 Jun 24; 1216:92-103. PMID: 18486110.
        View in: PubMed
      167. Hirata-Fukae C, Sidahmed EH, Gooskens TP, Aisen P, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neurosci Lett. 2008 Apr 25; 435(3):186-9. PMID: 18343582.
        View in: PubMed
      168. Tractenberg RE, Aisen P, Hancock GR, Rebeck GW. No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. Neurobiol Aging. 2009 Aug; 30(8):1327-8. PMID: 18083276.
        View in: PubMed
      169. Aisen P, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res. 2008 Feb; 5(1):73-82. PMID: 18288935.
        View in: PubMed
      170. Little JT, Walsh S, Aisen P. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Investig Drugs. 2008 Feb; 17(2):209-15. PMID: 18230054.
        View in: PubMed
      171. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen P. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008 Apr; 325(1):146-53. PMID: 18199809.
        View in: PubMed
      172. Aisen P. Leon Thal and the therapeutic age of Alzheimer's disease. Alzheimers Dement. 2008 Jan; 4(1 Suppl 1):S4-6. PMID: 18631999.
        View in: PubMed
      173. Aisen P. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Dis Assoc Disord. 2008 Jan-Mar; 22(1):4-5. PMID: 18317241.
        View in: PubMed
      174. Aisen P. An aspirin a day for Alzheimer's disease? Lancet Neurol. 2008 Jan; 7(1):20-1. PMID: 18068519.
        View in: PubMed
      175. Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen P, Kitamura Y, Matsuoka Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. Eur J Neurosci. 2007 Nov; 26(9):2458-68. PMID: 17970733.
        View in: PubMed
      176. Aisen P. Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006."--an appraisal. Alzheimers Dement. 2007 Oct; 3(4):446-8. PMID: 19595967.
        View in: PubMed
      177. Aisen P, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007 Sep; 4(4):473-8. PMID: 17908052.
        View in: PubMed
      178. Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen P, Duff K, Matsuoka Y. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 2007 Feb 12; 18(3):293-6. PMID: 17314674.
        View in: PubMed
      179. Tractenberg RE, Weiner MF, Aisen P, Kaye JA, Fuh JL. A simple method to rule out dementia with temporal orientation. Alzheimers Dement. 2007 Jan; 3(1):28-32. PMID: 19595914.
        View in: PubMed
      180. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen P. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci. 2007; 31(2):165-70. PMID: 17478890.
        View in: PubMed
      181. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen P, Kato A, Kinoshita N, Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006 Dec; 99(6):1555-63. PMID: 17083447.
        View in: PubMed
      182. Ferris SH, Aisen P, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S109-23. PMID: 17135805.
        View in: PubMed
      183. Aisen P. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimers Dement. 2006 Oct; 2(4):272-4. PMID: 19595898.
        View in: PubMed
      184. Tractenberg RE, Aisen P, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimers Dement. 2006 Oct; 2(4):303-13. PMID: 19595904.
        View in: PubMed
      185. Walsh SP, Raman R, Jones KB, Aisen P. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Dis Assoc Disord. 2006 Oct-Dec; 20(4 Suppl 3):S170-8. PMID: 17135810.
        View in: PubMed
      186. Aisen P. Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Alzheimers Dement. 2006 Jul; 2(3):153-4. PMID: 19595875.
        View in: PubMed
      187. Aisen P. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nat Clin Pract Neurol. 2005 Nov; 1(1):20-1. PMID: 16932488.
        View in: PubMed
      188. Gordon RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE, Aisen P, Doctor BP. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem Biol Interact. 2005 Dec 15; 157-158:239-46. PMID: 16256090.
        View in: PubMed
      189. Tractenberg RE, Aisen P, Chuang YL. One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline. Am J Alzheimers Dis Other Demen. 2005 Jul-Aug; 20(4):239-47. PMID: 16136848.
        View in: PubMed
      190. Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. An Abeta sequestration approach using non-antibody Abeta binding agents. Curr Alzheimer Res. 2005 Apr; 2(2):265-8. PMID: 15974928.
        View in: PubMed
      191. Aisen P. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. J Am Acad Nurse Pract. 2005 Mar; Suppl:5-7. PMID: 16033023.
        View in: PubMed
      192. Aisen P. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005; 19(12):989-96. PMID: 16332141.
        View in: PubMed
      193. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen P, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev. 2005; 11(4):353-68. PMID: 16614735.
        View in: PubMed
      194. Tractenberg RE, Weinstein M, Weiner MF, Aisen P, Fuh JL, Goldman N, Chuang YL. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology. 2005; 24(1-2):110-6. PMID: 15492486.
        View in: PubMed
      195. Walsh S, Aisen P. Inflammatory processes and Alzheimer's disease. Expert Rev Neurother. 2004 Sep; 4(5):793-8. PMID: 15853506.
        View in: PubMed
      196. Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen P, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem Biophys Res Commun. 2004 Jul 2; 319(3):733-7. PMID: 15184044.
        View in: PubMed
      197. Saunders PA, Aisen P. Georgetown University School of Medicine. Acad Med. 2004 Jul; 79(7 Suppl):S45-50. PMID: 15240216.
        View in: PubMed
      198. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen P, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004 Jan; 61(1):59-66. PMID: 14732621.
        View in: PubMed
      199. Aisen P, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 Jun 4; 289(21):2819-26. PMID: 12783912.
        View in: PubMed
      200. Aisen P, Schafer K, Grundman M, Thomas R, Thal LJ. NSAIDs and hypertension. Arch Intern Med. 2003 May 12; 163(9):1115; author reply 1115-6. PMID: 12742818.
        View in: PubMed
      201. Aisen P, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, Jagust W, Miller JW, Green R, Bell K, Sano M. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. Am J Geriatr Psychiatry. 2003 Mar-Apr; 11(2):246-9. PMID: 12611755.
        View in: PubMed
      202. Aisen P. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002 Sep; 1(5):279-84. PMID: 12849425.
        View in: PubMed
      203. Aisen P. Anti-inflammatory agents in Alzheimer's disease. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):405-9. PMID: 12169220.
        View in: PubMed
      204. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen P, Pasinetti GM. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 2002 May-Jun; 23(3):327-34. PMID: 11959394.
        View in: PubMed
      205. Aisen P. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. J Pain Symptom Manage. 2002 Apr; 23(4 Suppl):S35-40. PMID: 11992749.
        View in: PubMed
      206. Spielman L, Winger D, Ho L, Aisen P, Shohami E, Pasinetti GM. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathol. 2002 Feb; 103(2):157-62. PMID: 11810182.
        View in: PubMed